



Precision Medicine in Hepatobiliary Cancer: Preclinical and Clinical Evidence

Guest Editor:

Prof. Dr. Diego F. Calvisi

Institute of Pathology, University
of Regensburg, 93053
Regensburg, Germany

Deadline for manuscript
submissions:
closed (5 April 2022)

Message from the Guest Editor

Primary liver cancer (PLC) is a frequent and deadly tumor worldwide. PLC consists mainly of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in the adult, whereas hepatoblastoma (HB) is the prevalent hepatic malignancy in childhood.

In the last decade, as in many other tumor types, whole-genome sequencing studies together with a plethora of transcriptomic, proteomic, and metabolomic approaches have unraveled the molecular landscape of PLC. In addition, several in vitro and in vivo models have been generated to evaluate the possible vulnerability of tumors to innovative therapies. As a result, specific genetic and epigenetic events and peculiar metabolic features of the tumors have been identified. Effective and highly specific therapeutic approaches have been developed for some of them, and the concept of “precision medicine” (one patient = one treatment) has been established.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)